TY - JOUR T1 - Response to: ‘Correspondence on ‘A pilot study of tofacitinib for refractory Behçet’s syndrome’’ by Zou <em>et al</em> JF - Annals of the Rheumatic Diseases JO - Ann Rheum Dis SP - e101 LP - e101 DO - 10.1136/annrheumdis-2020-219828 VL - 82 IS - 4 AU - Jinjing Liu AU - Chan Zhao AU - Wenjie Zheng Y1 - 2023/04/01 UR - http://ard.bmj.com/content/82/4/e101.abstract N2 - We thank Zou and colleagues for their interests and insightful comments1 on our recently published work2 and are impressed by the encouraging results of tofacitinib on patients with refractory Behçet’s uveitis (BU).In this study, 5 mg two times per day tofacitinib was given to active patients with BU with prednisone reduced from 50 to 60 mg per day to 30 mg per day and withdrawal of conventional immunosuppressants (cyclosporine A or tacrolimus), which lead to treatment ‘success’ and ‘flare’ in 10 (76.9%) and 3 (23.1%) of the 13 included patients, respectively. Moreover, all the 10 patients responded to … ER -